Cardiovascular safety and benefits of GLP-1 receptor agonists
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) constitute a class of drugs for the treatment of type 2 diabetes, and currently, six different GLP-1RAs are approved. Besides improving glycemic control, the GLP-1RAs have other beneficial effects such as weight loss and a low risk of hypoglycemia. Treatment with the GLP-1RA lixisenatide has been shown to be safe in patients with type 2 diabetes and recent acute coronary syndrome. Furthermore, liraglutide and semaglutide have been shown to reduce cardiovascular (CV) disease (CVD) risk in type 2 diabetes patients with established and/or high risk of CVD. The CV safety of the remaining GLP-1RAs in type 2 diabetes patients with established and/or high risk of CVD remains uncertain, but ongoing CV outcome trials (CVOTs) will elucidate this within a few years. Areas covered: The aim of this review is to provide an overview of the existing GLP-1RAs with a particular focus on their clinical effects on CV risk factors and their CV safety and benefits. Expert opinion: Data on the CV risks and benefits associated with GLP-1RA treatment in patients with type 2 diabetes and high risk of CVD are emerging - and look promising (especially for liraglutide and semaglutide). Data from ongoing CVOTs will be crucial for the positioning of the individual GLP-1RAs in the treatment of patients with type 2 diabetes and high risk of CVD. However, the long-term CV safety and the potential of GLP-1RAs to prevent CVD in type 2 diabetes patients with less risk of CVD (e.g. newly diagnosed patients) remain uncertain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 4×
“unstable angina or heart failure, the individual MACE components, all-cause death, and microvascular outcomes [83].”
BackgroundInfluentialSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationType 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 2×
“The median follow-up period was 25 months [75].”
BackgroundGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 3×
“glucose excursions after a few weeks of treatment [11,38].”
BackgroundDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 19×
“In contrast to exenatide BID, treatment with exenatide QW is associated with a mean increase in heart rate of 2.6 bpm [33].”
BackgroundInfluentialBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803 · cited 1×
“was shown to be associated with increased risk of CVD [6].”
BackgroundNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 1×
“studies with GLP-1RAs in rodents revealed increased calcitonin levels and potential occurrence of thyroid C cell tumors [64].”
BackgroundThe Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665 · cited 13×
“This section will evaluate AEs and general GLP-1RA safety followed by a review of CV safety of the individual GLP-1RAs including a brief overview of their effects on CV risk factors (body weight, lipid profiles, SBP, and DBP) and CV safety data from phase III studies and CVOTs.”
BackgroundInfluentialSokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498 · cited 4×
“GLP-1 is subject to rapid inactivation by the ubiquitous enzyme dipeptidyl peptidase 4 (DPP-4) and renal clearance, which results in a circulating half-life for GLP-1 of only 1–2 min [4].”
BackgroundInfluentialPancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477
Wei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450
Moretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304
Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014) · Diabetes Care · doi:10.2337/dc13-2761 · Cited by 284 · cited 1×
“profile, but small improvements in LDL and HDL cholesterol have been shown rather consistently [65,84].”
BackgroundElbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1398 · Cited by 279
Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276
Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Nauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care · doi:10.2337/dc15-0165 · Cited by 233
Sun, F., Wu, S., Wang, J., Guo, S., Chai, S., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.11.008 · Cited by 232 · cited 1×
“and total and LDL cholesterol have also been associated with exenatide QW treatment [69,77].”
BackgroundUmapathysivam, M. M., Lee, M. Y., Jones, K. L., Annink, C. E., Cousins, C. E., Trahair, L. G., Rayner, C. K., Chapman, M. J., Nauck, M. A., Horowitz, M., et al. (2014) · Diabetes · doi:10.2337/db13-0893 · Cited by 193 · cited 1×
“glucose excursions after a few weeks of treatment [11,38].”
BackgroundKapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C. B., & Flint, A. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.443 · Cited by 175
Lovshin, J. A., Barnie, A., DeAlmeida, A., Logan, A., Zinman, B., & Drucker, D. J. (2015) · Diabetes Care · doi:10.2337/dc14-1958 · Cited by 168 · cited 2×
“increases natriuresis without affecting ANP levels [22,23].”
BackgroundThe Glucagon-Like Peptide-1 Receptor—or Not?
Pyke, C., & Knudsen, L. B. (2013) · Endocrinology · doi:10.1210/en.2012-2124 · Cited by 154
The FLAT-SUGAR Trial Investigators (2016) · Diabetes Care · doi:10.2337/dc15-2782 · Cited by 135
Kumarathurai, P., Anholm, C., Larsen, B. S., Olsen, R. H., Madsbad, S., Kristiansen, O., Nielsen, O. W., Haugaard, S. B., & Sajadieh, A. (2017) · Diabetes Care · doi:10.2337/dc16-1580 · Cited by 96 · cited 1×
“Other hypotheses suggest that the elevated heart rate could be due to impaired parasympathetic activity inflicted by GLP-1R agonism, and a third suggests that the increased heart rate constitutes a compensatory phenomenon in relation to GLP-1RA-induced reduction in blood pressure [27,28].”
BackgroundNakatani, Y., Kawabe, A., Matsumura, M., Aso, Y., Yasu, T., Banba, N., & Nakamoto, T. (2016) · Diabetes Care · doi:10.2337/dc15-1437 · Cited by 77
Sun, F., Yu, K., Yang, Z., Wu, S., Zhang, Y., Shi, L., Ji, L., & Zhan, S. (2012) · Experimental Diabetes Research · doi:10.1155/2012/230624 · Cited by 58
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Diamant, M., & van Raalte, D. H. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0507 · Cited by 54 · cited 1×
“Other hypotheses suggest that the elevated heart rate could be due to impaired parasympathetic activity inflicted by GLP-1R agonism, and a third suggests that the increased heart rate constitutes a compensatory phenomenon in relation to GLP-1RA-induced reduction in blood pressure [27,28].”
BackgroundCardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
Kang, Y. M., & Jung, C. H. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.2.258 · Cited by 51
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49 · cited 1×
“before any firm conclusions can be made [62,63].”
BackgroundSimó, R., Guerci, B., Schernthaner, G., Gallwitz, B., Rosas-Guzmàn, J., Dotta, F., Festa, A., Zhou, M., & Kiljański, J. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0279-z · Cited by 47
Plutzky, J., Garber, A., Falahati, A., Toft, A. D., & Poulter, N. R. (2009) · Canadian Journal of Diabetes · doi:10.1016/s1499-2671(09)33072-5 · Cited by 33
Chalmer, T., Almdal, T. P., Vilsbøll, T., & Knop, F. K. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.975205 · Cited by 31 · cited 2×
“before any firm conclusions can be made [62,63].”
BackgroundSelf-citation
Cited by
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Self-citationA Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
Griffith, D. A., Edmonds, D. J., Fortin, J.-P., Kalgutkar, A. S., Kuzmiski, J. B., Loria, P. M., Saxena, A. R., Bagley, S. W., Buckeridge, C., Curto, J. M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01856 · Cited by 192
Nauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1825 · Cited by 94
Konig, M., Riddle, M. C., Colhoun, H. M., Branch, K. R., Atisso, C. M., Lakshmanan, M. C., Mody, R., Raha, S., & Gerstein, H. C. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01386-4 · Cited by 73
Metadata
- Authors
- Dalsgaard, N. B., Brønden, A., Vilsbøll, T., & Knop, F. K.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2017-01-19
- Volume
- 16
- Issue
- 3
- Pages
- 351-363
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2571824959
- Cited by
- 34
- References
- 45
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.